Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Seneca Biopharma approved for merger with Leading Biosciences » 07:07
04/26/21
04/26
07:07
04/26/21
07:07
SNCA

Seneca Biopharma

$1.60 /

+0.015 (+0.95%)

Seneca Biopharma…

Seneca Biopharma disclosed on April 23, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences. The Merger is expected to close on or about April 27, and the new combined company, Palisades Bio, is expected to begin trading on the Nasdaq Capital Market on or about April 28 under the ticker "PALI". Seneca and LBS will announce the final exchange ratio prior to the common stock commencing trading on or about Wednesday, April 28.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.60 /

+0.015 (+0.95%)

Hot Stocks
Leading BioSciences announce data from open label GI study with LB1148 » 07:05
04/20/21
04/20
07:05
04/20/21
07:05
SNCA

Seneca Biopharma

$1.55 /

+0.155 (+11.11%)

Leading BioSciences, a…

Leading BioSciences, a company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148. Although these are early data in a limited number of patients, the data may support the company's ongoing Phase 2 clinical trial to evaluate the impact of LB1148 on return to bowel function, length of stay, and postoperative intra-abdominal adhesions. In the LBS-IST-POI-101 study, three of the 11 patients enrolled underwent follow-up surgical procedures. For two of these patients, the patient had no intra-abdominal adhesions at the time of the follow-up surgery. A third patient's follow-up surgery was conducted on an emergent basis 14 days postoperatively by a surgeon who was not participating as an investigator in the clinical trial, and so the extent and severity of adhesions were not formally assessed. Although an official evaluation of adhesions was not provided, the surgical notes do not describe any adhesions during the surgery. Generally, treatment with LB1148 was well tolerated. AEs were not considered unexpected in this patient population. None of the AEs or SAEs reported were considered drug-related by the sponsor-investigator.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.55 /

+0.155 (+11.11%)

Hot Stocks
Leading BioSciences provides update to Seneca stockholders on merger closing » 07:09
04/19/21
04/19
07:09
04/19/21
07:09
SNCA

Seneca Biopharma

$1.40 /

-0.025 (-1.76%)

Leading BioSciences…

Leading BioSciences released a video message from its CEO, Dr. Tom Hallam updating stockholders in Seneca Biopharma on what to expect in the days following a positive vote to approve Proposal #1, the reverse stock split. Seneca recently adjourned the virtual Special Meeting until April 23, 2021 at 11:00 a.m. ET. The video also described upcoming potential milestones in three categories: public events, regulatory milestones, and clinical data readouts. Public Events: LBS anticipates participating in multiple investor events, including healthcare conferences held by investment banks and medical conferences to release more detailed clinical data. Further, LBS is organizing a Medical Leader Event Series that will be open to the public. Regulatory Milestones: LBS is preparing several discussions with the FDA and other global regulatory agencies regarding our programs that will form the basis for regulatory submissions for approvals around the world. Clinical Milestones: LBS anticipates announcing data from a Phase 2 GI surgery study designed to show both a shortened time to the return of bowel function and a reduction of postoperative intra-abdominal adhesions. LBS also is working on commencing studies for treating neonates with LB1148 to accelerate the return of bowel function.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.40 /

-0.025 (-1.76%)

Over a month ago
Hot Stocks
Seneca Biopharma in favor of proposed merger with Leading Biosciences » 07:09
03/30/21
03/30
07:09
03/30/21
07:09
SNCA

Seneca Biopharma

$1.51 /

-0.035 (-2.27%)

In a letter to…

In a letter to stockholders, Seneca Biopharma stated, in part, "We are writing to reaffirm our strong belief that Seneca Biopharma's proposed merger with Leading Biosciences is in the best interests of all stockholders and urge your support at the company's Special Meeting scheduled for April 9, 2021. After a thorough review process that included an evaluation of multiple alternatives, Seneca's Board ultimately concluded the Merger offers the most compelling opportunity for its stockholders. Seneca's board recommends voting in favor of the proposals."

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.51 /

-0.035 (-2.27%)

Hot Stocks
Seneca Biopharma's merger with Leading Biosciences recommended by ISS » 07:07
03/17/21
03/17
07:07
03/17/21
07:07
SNCA

Seneca Biopharma

$1.56 /

+0.02 (+1.30%)

Seneca Biopharma…

Seneca Biopharma announced that independent proxy advisory firm Institutional Shareholder Services - ISS - has recommended that Seneca stockholders vote in support of the proposed merger with Leading BioSciences and vote for the proposals for the reverse stock split and issuance of shares in connection with the merger, to be considered and voted on at Seneca's March 24, 2021 special meeting of stockholders.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.56 /

+0.02 (+1.30%)

Over a quarter ago
Hot Stocks
Seneca Biopharma regains compliance with Nasdaq listing rules » 08:07
01/25/21
01/25
08:07
01/25/21
08:07
SNCA

Seneca Biopharma

$1.43 /

+0.06 (+4.38%)

Seneca Biopharma…

Seneca Biopharma announced that it received notice from The NASDAQ Stock Market on January 22 indicating that the company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The NASDAQ Capital Market.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.43 /

+0.06 (+4.38%)

Hot Stocks
Seneca Biopharma reports data from Phase 2 study of NSI-566 in China » 08:03
01/20/21
01/20
08:03
01/20/21
08:03
SNCA

Seneca Biopharma

$1.34 /

+ (+0.00%)

Seneca Biopharma…

Seneca Biopharma announced preliminary, top-line results of the company's placebo controlled Phase 2 stroke study that was conducted in Beijing, China. The trial was designed to evaluate the relative safety of the company's human neural stem cell therapy, NSI-566, in patients with stable deficits in motor function resulting from ischemic stroke. Patients were eligible for the trial if they had documented history of ischemic stroke at least four months, but no more than 24 months, before surgery. The study enrolled 23 patients who were randomly assigned to treatment or placebo arms. Patients in the treatment arm received intracerebral injection of 72M stem cells, whereas those in the placebo group underwent a sham surgery procedure. Secondary objectives to evaluate efficacy were performed by qualified assessors who were blinded to treatment assignment, and included the Fugl-Meyer Motor Score, an assessment of upper and lower motor function that comprises a 100 point scale and is widely used following stroke. Patients enrolled in the treatment and placebo arms had similar baseline FMMS scores before surgery. While most participants showed some improvement in FMMS from pre-surgery scores, the mean improvement after one year was greater in those participants receiving NSI-566 compared to placebo, though the difference between groups did not reach statistical significance using the approximate Student's t-test. Two participants in the treatment arm showed clinically important improvements of 32 and 44 points on the FMMS following treatment with NSI-566, whereas the largest improvement observed in the placebo group was 17 points. Participants in the treatment arm experienced a total of three serious adverse events that were considered by the investigator to be probably or possibly related to treatment, whereas no patients in the placebo arm experienced SAEs. Treatment-related SAEs were resolved with standard medical care and were limited to impaired healing at the incision site and wound dehiscence in one patient, and impaired hepatic function in another.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.34 /

+ (+0.00%)

Hot Stocks
Leading BioSciences announces Fast Track Designation for LB1148 » 08:49
01/13/21
01/13
08:49
01/13/21
08:49
SNCA

Seneca Biopharma

$1.30 /

-0.07 (-5.11%)

Leading BioSciences, a…

Leading BioSciences, a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma to form Palisade Bio, Inc., announced that the U.S. Food and Drug Administration has granted Fast Track Designation to LB1148 for the treatment of postoperative gastrointestinal dysfunction associated with pediatric heart surgery. Previously, LBS announced positive topline data from a Phase 2, randomized, double-blind, placebo-controlled, study that enrolled 120 adult open-heart surgery patients. This trial evaluated return of bowel function in adult patients undergoing open-heart surgery with cardiopulmonary bypass. The LB1148-treated group demonstrated a statistically significant improvement of approximately 30% in the median time to return of normal bowel function as compared to the placebo treatment group. Generally, treatment with LB1148 was well tolerated. Adverse events were similar between the treatment groups and not unexpected for the subject population. In addition to adult open-heart surgery patients, there is a tremendous unmet need for improving GI recovery in neonates undergoing heart surgery. By accelerating a return of GI function and full feeding following surgery, LB1148 may minimize the risk of developmental delays and other serious complications. LBS is planning to initiate a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial of LB1148 in neonatal patients undergoing elective on-pump open-heart surgery to correct congenital heart defects in 2021.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.30 /

-0.07 (-5.11%)

Hot Stocks
Leading BioSciences announces topline data from gastrointestinal surgery study » 08:55
01/08/21
01/08
08:55
01/08/21
08:55
SNCA

Seneca Biopharma

$1.06 /

+0.0675 (+6.80%)

Leading BioSciences, a…

Leading BioSciences, a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma to form Palisade Bio, Inc. announced that data from an open-label study demonstrated that patients treated with LB1148 had a statistically significant shorter length of stay in the hospital than the expected length of stay based on their billing code at admission. The data are from an open-label, investigator-sponsored, single-arm study that enrolled 11 patients and evaluated 10 patients undergoing elective gastrointestinal surgery. Upon admission, patients are typically assigned a billing code that is associated with an expected geometric mean length of stay. The GMLOS is derived from hundreds of thousands of admissions and represents an expected mean length of stay. The actual length of stay of patients treated with LB1148 in this clinical trial was compared to the expected GMLOS. LB1148 treated patients had a statistically significant reduction in hospital length of stay by 1.3-days when compared with expected length of stay based on their billing code at admission. The improvement in length of stay observed in LB1148-treated patients compared favorably to that previously reported from clinical trials of ENTEREG which were between 0.3 days and 0.7 days. Following GI surgery, postoperative return of bowel function is often a limiting determinant of hospital discharge. The mean time for a first bowel movement in LB1148-treated patients in this clinical trial following surgery was 2.43 days. As a reference, in a clinical trial of the approved-drug, ENTEREG, which enrolled a similar elective bowel resection surgery patient population, the mean time for first bowel movement in the placebo treated patients was 4.7 days.

ShowHide Related Items >><<
SNCA Seneca Biopharma
$1.06 /

+0.0675 (+6.80%)

Hot Stocks
Seneca Biopharma trading resumes  07:30
12/17/20
12/17
07:30
12/17/20
07:30
SNCA

Seneca Biopharma

$0.77 /

-0.02 (-2.53%)

 
ShowHide Related Items >><<
SNCA Seneca Biopharma
$0.77 /

-0.02 (-2.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.